What is the future development trend of pharmaceutical industry?

China pharmaceutical market will continue to develop at a high speed;

1, transformation and innovation. This must be the best path, and innovation must be the general trend in the future. However, because the research and development cycle of innovative drugs is 5-8 years, it is necessary to deploy an R&D team and spend a lot of R&D investment, not this year, but next year. Therefore, although transformation and innovation is the best track, it takes time.

If it is difficult for him to innovate, he might as well consider the second way. For example, the product patent has expired, but due to the difficulty of its own dosage form, there may be some production barriers. This may be the second way. Assuming that the innovation fails, he may consider developing drugs that are difficult to imitate. Typical companies such as Health Yuan are doing very well.

3. If the second one is more difficult, the third path is to extend the product line. A listed generic drug will face centralized procurement in the short term, and if it fails first, it will produce 10 and 20 models. Finally, some products will enter centralized procurement, which will bring increment. As long as the echelon of products listed every year is guaranteed, cash flow and profit can be realized in the future. This is also a road. In the current period, some companies will also make arrangements in this regard.

4. From the summary of generic drug companies, it can be seen that the existing pipelines should pay more attention to the future influence of centralized procurement, what is the future steady-state situation, and we will pay more attention to new pipelines and future development directions, which are the general characteristics and research methods of chemical generic drugs.

5. Prescription drugs of traditional Chinese medicine are also a relatively low-level market segment at present. We believe that the core reason is that most of the products being researched by Chinese medicine enterprises are relatively few, which may be more about echelon analysis of existing product lines, which is somewhat out of line with the current direction of innovation, so the attention of Chinese medicine is not so high at present.

On the one hand, we need to pay attention to what is the category of its existing products, whether the category is a big field, whether the product price will be under pressure, and whether it will enter medical insurance in the future. This is a point that we need to pay attention to.